ImmunityBio, Inc.
IBRX
$2.84
$0.176.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 129.10% | 21.03% | |||
| Total Other Revenue | -97.69% | 127.63% | |||
| Total Revenue | 118.71% | 23.68% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 117.94% | 23.68% | |||
| SG&A Expenses | -21.61% | 16.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.19% | -10.89% | |||
| Operating Income | 7.16% | 13.52% | |||
| Income Before Tax | -119.50% | 30.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -119.11% | 30.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 17.65% | -26.09% | |||
| Net Income | -119.14% | 30.99% | |||
| EBIT | 7.16% | 13.52% | |||
| EBITDA | 7.14% | 13.90% | |||
| EPS Basic | -88.35% | 34.50% | |||
| Normalized Basic EPS | -90.58% | 35.19% | |||
| EPS Diluted | -62.92% | 35.03% | |||
| Normalized Diluted EPS | -90.96% | 35.16% | |||
| Average Basic Shares Outstanding | 16.36% | 5.36% | |||
| Average Diluted Shares Outstanding | 16.15% | 5.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||